Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Inclusion Criteria: * Male and female subjects \>= 18 years of age * Clinical diagnosis of nonalcoholic steatohepatitis (NASH) assessed by the presence of body imaging criteria (ultrasound, computed tomography \[CT\], or magnetic resonance imaging \[MRI\]), or liver biopsy up to six months prior to enrollment without suspicious nodules or cancer * Screening transient elastography liver stiffness \>= 12 kPa (which correlates with F3 fibrosis and more) and \< 25 kPa. Historic transient elastography within 0-4 weeks prior to the date of the screening visit is acceptable. Patients with liver stiffness \>= 10 and \< 12 kPA with clinical evidence of cirrhosis based on any of the following criteria would also be eligible. * Imaging diagnosis of nodular liver with splenomegaly or recanalized umbilical vein * MRE \>= 5 kPa * Fibrosis (FIB)-4 \> 2.67 or platelet count \< 150,000 mL * Liver biopsy \< 5 years with meta-analysis of histological data in viral hepatitis (METAVIR) stage 4 or Ishak stage 5-6 * Controlled attenuation parameter score or liver steatosis analysis (LiSA) of \>= 260 dB/m and any single component of metabolic syndrome (ATP3 criteria) or historic liver biopsy within 0 - 6 months prior to the date of the screening visit consistent with nonalcoholic steatohepatitis (NASH) (defined as the presence of steatosis, inflammation, and ballooning), with stage 3-4 fibrosis according to the NASH Clinical Research Network classification (or equivalent) * Leukocytes \>= …